STOCK TITAN

Tandem Diabetes (TNDM) COO exercises RSUs; shares withheld for taxes

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos exercised restricted stock units and had shares withheld for taxes. On April 15, 2026, he converted 3,636 restricted stock units into an equal number of common shares at a $0.00 exercise price under a long-term incentive plan.

To cover tax withholding on the RSU vesting, 1,926 common shares were withheld by Tandem Diabetes Care Inc. at $20.66 per share, with no shares sold on the market. Following these transactions, he directly holds 25,772 shares of common stock and 18,181 restricted stock units.

Positive

  • None.

Negative

  • None.
Insider Kyrillos Jean-Claude
Role EVP & Chief Operating Officer
Type Security Shares Price Value
Exercise Restricted Stock Unit 3,636 $0.00 $0.00
Exercise Common Stock 3,636 $0.00 $0.00
Exercise Price or Tax Liability Common Stock 1,926 $20.66 $40K
Holdings After Transaction: Restricted Stock Unit — 18,181 shares (Direct); Common Stock — 25,772 shares (Direct)
Footnotes (4)
  1. F1. Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
  2. F2. Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
  3. F3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
  4. F4. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
RSUs exercised 3,636 units Restricted Stock Units converted to common stock on April 15, 2026
Shares withheld for taxes 1,926 shares Common shares withheld to satisfy tax withholding at $20.66 per share
Tax withholding price $20.66 per share Value used for shares withheld to cover tax obligations
Common shares after transaction 25,772 shares Direct holdings of common stock following Form 4 transactions
Restricted stock units after transaction 18,181 units RSU holdings following exercise of 3,636 units
Restricted Stock Unit financial
"security_title: "Restricted Stock Unit" and description of RSUs"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
tax withholding requirements financial
"Shares withheld by Tandem Diabetes Care Inc. to satisfy tax withholding requirements"
Long-Term Incentive Plan financial
"pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan"
A long-term incentive plan is a company program that pays executives or employees with stock, options, or cash tied to multi-year performance goals, where the rewards become theirs only after meeting conditions over time. Think of it as a delayed bonus or retirement-style reward that aligns employees’ interests with shareholders by encouraging them to boost long-term value; investors watch these plans because they affect pay costs, share dilution and management incentives.
vesting financial
"RSU vest as to thirty-three percent (33%) of the total number of shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
contingent right financial
"Each RSU represents a contingent right to receive either one share of common stock"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Tandem Diabetes Care (TNDM) report for Jean-Claude Kyrillos?

Tandem Diabetes Care reported that EVP & Chief Operating Officer Jean-Claude Kyrillos exercised 3,636 restricted stock units into common shares. The transaction reflects scheduled equity compensation under the company’s 2023 Long-Term Incentive Plan rather than an open-market stock purchase or sale.

Were any Tandem Diabetes Care (TNDM) shares sold by Jean-Claude Kyrillos in this Form 4?

No, the filing states that no shares were sold. Instead, 1,926 common shares were withheld by Tandem Diabetes Care to satisfy tax withholding obligations related to the vesting of restricted stock units, a common administrative mechanism for equity compensation.

How many Tandem Diabetes Care (TNDM) shares does Jean-Claude Kyrillos own after the reported transactions?

After the reported transactions, Jean-Claude Kyrillos directly holds 25,772 shares of Tandem Diabetes Care common stock. The filing also shows he holds 18,181 restricted stock units that represent contingent rights to receive additional shares or cash under the company’s incentive plan.

What restricted stock units vested for Jean-Claude Kyrillos at Tandem Diabetes Care (TNDM)?

On April 15, 2026, 3,636 restricted stock units vested and were converted into an equal number of common shares. These RSUs were awarded on July 15, 2024 under Tandem Diabetes Care’s 2023 Long-Term Incentive Plan and follow a scheduled vesting timetable.

How are the remaining restricted stock units for Jean-Claude Kyrillos at Tandem Diabetes Care (TNDM) structured?

The filing indicates that restricted stock units vest 33% on July 15, 2025, with the remaining shares vesting in eight equal quarterly installments. Each RSU represents a contingent right to receive one share of common stock or cash, at the issuer’s discretion, under the 2023 Long-Term Incentive Plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kyrillos Jean-Claude

(Last)(First)(Middle)
12400 HIGH BLUFF DRIVE

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP & Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/15/2026M3,636A$027,698D
Common Stock04/15/2026F(1)1,926D$20.6625,772D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(2)(3)04/15/2026M3,636 (4) (4)Common Stock3,636$018,181D
Explanation of Responses:
1. Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
2. Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
4. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
Remarks:
/s/ Shannon M. Hansen, Attorney-in-Fact for Jean-Claude Kyrillos04/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)